Printer Friendly
The Free Library
19,585,946 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

American BioMed Inc. signs Labamo S.A.C.V. as its exclusive distributor for Mexico.


The Woodlands, Texas--(BUSINESS WIRE)--June 24, 1996--American BioMed Inc. (OTC OTC

See: Over-the-counter.


OTC

See over-the-counter market (OTC).
 BB:ABMI ABMI Autologous Bone Marrow Infusion ), of The Woodlands, Monday announced that it has signed an exclusive distribution agreement with Labamo S.A.C.V. for marketing and distribution of the company's current product line in Mexico.

Labamo's responsibilities will include all registrations for its product line in that country as well. This will enable the company to participate in the public institution tender process, which accounts for the largest share of the Mexican Market.

Arthur S. Przybyl, VP Sales and Marketing stated: "The exclusive distributorship arrangement with Labamo represents a continuing strategy to expand American BioMed's worldwide market presence. Labamo is an excellent partner and currently represents other healthcare companies such as W.L. Gore, Meadox Medical and ATS Medical in Mexico. Their proven marketing experience in Mexico will serve to help us attain our marketshare objectives." Correspondence with other U.S. and International medical companies is ongoing in the company's continuing effort to expand marketshare through strategic alliances, joint ventures or licensing agreements.

American BioMed Inc. utilizes state of the art technology to develop, manufacture and market minimally invasive medical, surgical and diagnostic devices which deliver unique advantages through advanced science. Over 25 patents cover its technologies competing in an industry with combined markets estimated at over $10-billion annually. The devices include but are not limited to the OmniCath(r) atherectomy catheter, as well as the company's nine patented FDA FDA
abbr.
Food and Drug Administration


FDA,
n.pr See Food and Drug Administration.

FDA,
n.pr the abbreviation for the Food and Drug Administration.
 approved unique all-silicone balloon catheters balloon catheter
n.
A catheter with an inflatable balloon at its tip, used especially to expand a partially obstructed blood vessel or bodily passage and to measure blood pressure in a blood vessel. Also called balloon-tip catheter.
. These consist of thermodilution heart, thrombectomy thrombectomy /throm·bec·to·my/ (throm-bek´tah-me) surgical removal of a clot from a blood vessel.

throm·bec·to·my
n.
Excision of a thrombus.
, urinary bladder urinary bladder
n.
A musculomembranous elastic receptacle in the anterior part of the pelvic cavity serving as the temporary storage place for urine.
 and angioscopy catheters. The OmniStent(tm) and accompanying stent technology is used to support diseased blood vessels Blood vessels

Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names.
. Other devices such as minimally invasive spinal instruments are also under development.

CONTACT: Thomas E. Waite & Associates Inc.

407/324-1606/Fax 407/324-0664
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jun 24, 1996
Words:292
Previous Article:Imagex announces new radiology licensing agreement to generate a minimum of $1.0 million in annualized gross revenues previously announced new...
Next Article:Ericsson and Pacific Bell win National Access Award from Self Help for the Hard of Hearing.
Topics:



Related Articles
AMERICAN BIOMED REPORTS PROGRESS IN COMMERCIALIZATION.
Comarex Inks EM. TV Jr. Deal.
Turning Kansas City Into Biomed Valley.
ONCOMAB/MEDAREX TO DEVELOP/COMMERCIALIZE CANCER ANTIBODIES.
ARC AWARDS $300,000 TO PANVAX TO DEVELOP FMDV VACCINE.
Trust breaks ground on $145m lab and office complex.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles